Bristol Myers Squibb, BioNTech report 36.7% response rate for pumitamig combination in Phase 2 lung cancer trial

By Public Technologies
  • Bristol Myers Squibb and BioNTech reported encouraging Phase 2 results for investigational pumitamig with docetaxel in previously treated advanced lung cancer.
  • ROSETTA Lung-107 showed tumor responses across cancer subtypes and PD-L1 expression levels in patients whose disease progressed following immunotherapy with chemotherapy.
  • Results presented today at the ESMO Congress 2026 showed encouraging progression-free survival, supporting further development in second-line non-small cell lung cancer.
  • The combination had a manageable safety profile, with no new safety signals or pumitamig-related deaths.
  • The findings expand pumitamig’s lung cancer evidence base as the partners advance four global Phase 3 trials.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief on October 25, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.